M. S. Biotechnology Program Highlights
Where Are Our Graduates Now?
2010-2011 class of four students:
MBA/PhD Student at Wake Forest University
BioQuantitative Analyst at Children’s Healthcare of Atlanta
Indiana State Department of Health
Intellectual property associate at Faegre Baker Daniels, LLP
2011-2012 class of thirteen students:
Attorney at Woodard, Emhardt, Moriarty, McNett & Henry LLP
Scientist, Eli Lilly
Research associate, IU-B (2)
Intelligence Analyst at Northrop Grumman Corporation
Ph.D. candidate, UT Southwestern Univ.
Ph.D candidate, Purdue University
PhD candidate, Univ. of Kentucky
Development Leader at Syngenta
Patent Agent, The Noblitt Group
IU Medical School
Ph.D candidate, IU-B
Quality Lab Associate, Baxter
2012-13 class of six students:
Research Associate, IU-B
Drosphila Stocks Manager, IU Drosophila Stocks Center
Scientist, International Health Management Associates (2)
Masters Student, Nanotechnology, Louisiana Tech
Pharmacy Technician, CVS
Qi, X. et al. 2011. Cell-penetrating peptides derived from viral capsid Proteins. Molec. Plant-Microbe Interact. 24:25-36.
Fontaine, S. et al. 2012. Replacement of charged and polar residues in the coiled-coiled interface of huntingtin-interacting protein 1 (HIP1) causes aggregation and cell death. FEBS Lett. In press.
Bauer S. P. Insights into the Huntingtin Binding and Coiled-Coil Domains of Huntingtin-Interacting Protein 1 and Huntingtin-Associated Protein 1. Masters Thesis. Submitted Apr. 24, 2012.
Bush, K. et al. 2013. Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. Intl. J. Antimicrob. Agents 41:1-4.Hayakawa, K., et al. 2013. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum b-lactamase in a large U.S. medical center. Antimicrobial Agents & Chemotherapy 57:4010-4018.
Presentations at Scientific Conferences
Pannell, M. et al. 2012. Characteristics of the Novel Group 2b b-Lactamase SHV-141. Annual Meeting of the American Society for Microbiology.
Zheng, Y et al. 2012. β-lactam Resistance In Enterobacteriaceae Isolated From Fecal Samples Of Branta canadensis Resident In Dupage County, Illinois. Annual Meeting of the American Society for Microbiology, Indiana Branch.
Bush, K, et al. 2012. Surveillance and Enzyme Characterization of Carbapenem-Resistant Enterobacteriaceae (CRE) in an Indiana Health Care Setting (2009-2012). Conference on Antimicrobial Agents and Chemotherapy.
Hayakawa, K. et al. 2012. Differences Between Patients with Isolates of CTX-M Type Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli Compared to non-CTX-M Type ESBL-Producing E. coli. Conference on Antimicrobial Agents and Chemotherapy.
Hayakawa, K. 2012. A case-control study of risk factors and outcomes for isolation of CTX-M extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in a large U.S. medical center. Infectious Disease Society of America.
Li H. et al. 2013. Carbapenem-Resistant Enterobacteriaceae (CRE) Encoding KPC and VIM Carbapenemases from Indiana. Infectious Disease Society of America
M. Estabrook et al. 2013. In vitro activity of CXA-201 (Ceftolozane-Tazobactam) against 200 CTX-M-producing Escherichia coli clinical isolates. Abstract # 1169. Conference on Antimicrobial Agents and Chemotherapy.
Denys G. et al. 2013. Changing epidemiology and molecular characterization of carbapenem-resistant Enterobacteriaceae (CRE) in Indiana Health Care Centers (HCCs) over a 3-year period. Conference on Antimicrobial Agents and Chemotherapy.